insulin drugs glp 1 receptor agaonist market Glp-1 Analogues Size, Share & Growth Drivers By 2034 Europe Insulin Drugs And Glucagon-Like

See more: New anti-obesity drugs represent challenge, opportunity for employers Despite the implementation of cost-containment strategies in recent years, GLP-1s continue to drive a substantial portion of the increase in pharmacy spending

the overall 12-month discontinuation rate for GLP-1 agonists is estimated at 36.5%, with higher rates observed in patients with obesity alone compared to those with type 2 diabetes

9 To avoid hypoglycemic events when dispensing exenatide in combination with an SU, it is important to reduce the SU dose on initiation of exenatide and when titrating the exenatide dose upward

H.MacConellL

2022;10(18):e15462

Many patients later restarted the original medication or switched to an alternative obesity treatment